MacuLogix

Harrisburg,  PA 
United States
http://www.maculogix.com
  • Booth: 47


Lead the revolution in AMD with AdaptDx Pro guided by Theia

MacuLogix® equips eye care professionals with the only disease management platform to effectively diagnose, manage and treat patients with age-related macular degeneration (AMD). By leveraging the science of dark adaptation through its AdaptDx® and AdaptDx Pro™ guided by Theia™, MacuLogix is working to eliminate preventable blindness caused by AMD—a chronic, progressive disease that impacts nearly 200 million people worldwide and goes undiagnosed in 25 percent of patients. The company's dark adaptation functional testing technology combined with its MeyePractice™ software creates a powerful disease management platform that incorporates patient, clinical and business management data into one simple dashboard. MacuLogix’s Practice Management Consultants also help eye care professionals maximize their investment to benefit their patients and practice.

Brands: AdaptDx Pro™ provides precision eye-tracking technology to capture an accurate measurement of dark adaptation function. Powered by AI, our on-board technician, Theia™, guides patients through the test


 Videos

AdaptDx Pro Overview I Breakthrough Eye Care Technology
AdaptDx Pro Testing_Embracing a New Standard of Care for AMD
Change the Future of Eye Care with AdaptDx Pro
AdaptDx Pro | Empowering Techs as AMD Champions
AdaptDx Pro | Improving Dark Adaptation Testing for Patients

 Press Releases

  • The next generation of dark adaptation testing features a wearable headset and an artificial intelligence-driven onboard technician.

    HARRISBURG, PENNSYLVANIA, JANUARY 14, 2020–MacuLogix®, Inc., the only company to equip eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), announces the next generation of dark adaptation functional testing with the introduction of the AdaptDx Pro™ guided by Theia.™

    The company’s original AdaptDx® automated dark adaptometer was introduced in 2014 and has since been used by more than 1,000 eye care professionals to identify and monitor AMD. The new AdaptDx Pro headset was custom-designed and tested for patient comfort and includes all the functionality and accuracy of the company’s table-top dark adaptometer. As a self-contained wearable headset, the AdaptDx Pro requires no darkroom or external computer and features an artificial intelligence-driven onboard technician named Theia.™  After the in-office technician selects the testing protocol and places the device on the patient’s head, Theia takes over to facilitate a reliable, consistent testing experience by using automated instructions and adaptive feedback spoken directly to the patient.

     “What makes the AdaptDx Pro so special is that it combines high-tech innovation and high-touch patient care without sacrificing functionality or results,” says William McPhee, President and CEO at MacuLogix. “AdaptDx Pro makes it simple to fit dark adaptation testing into any practice workflow and Theia frees up the technician to focus on other valuable tasks.”

    Impaired dark adaptation is the earliest biomarker of AMD. Often manifested as night vision problems, this functional impairment becomes apparent years before drusen are visible. Therefore, assessing how well patients’ eyes can adapt from bright light to darkness makes it possible to detect AMD at a subclinical stage. AdaptDx Pro guided by Theia is a revolutionary new way to measure dark adaptation in a clinical setting quickly and effectively, using an objective, functional measurement called the Rod Intercept™ (RI™). Importantly, impaired dark adaptation as measured by the AdaptDx Pro is 90% specific and sensitive to AMD.

    “Patients and staff love Theia. Her gentle coaching, combined with the well-designed, comfortable headset puts patients at ease and frees up technicians while testing takes place,” says MacuLogix’s clinical advisor Jeffry Gerson, OD, FAAO. “Ultimately, the AdaptDx Pro enables us to test more patients to find disease that we may have otherwise missed and start those patients on a treatment plan to slow disease progression.”

    Years of development went into creating this one-of-a-kind medical device to improve the testing experience and make modern AMD management practical in almost any optometry or ophthalmology office.

    “After spending more than two years developing this technology, I firmly believe the AdaptDx Pro and Theia are going to change the future of AMD by eliminating virtually every barrier to in-office diagnosis and management of age-related macular degeneration,” says MacuLogix Co-founder and Chief Technology Officer Gregory Jackson, PhD. “Not only is the entire experience improved for everyone involved, but the addition of Theia’s artificial intelligence helps ensure consistent, reliable testing results.”

    The AdaptDx Pro launches today and the company has committed to providing current AdaptDx table-top device owners with the first opportunity to upgrade to the AdaptDx Pro. Eye care professionals can experience the AdaptDx Pro guided by Theia in person and learn about purchase and subscription pricing options at variety of local and national events, including SECO (Booth 838) and Vision Expo East (Booth MS4733) or online at www.maculogix.com.

    About MacuLogix®

    MacuLogix, Incequips eye care professionals with the instrument, tools and education needed to effectively diagnose, manage and treat patients with age-related macular degeneration (AMD). By leveraging the science of dark adaptation through its AdaptDx® and AdaptDx Pro™ guided by Theia™, MacuLogix is working to eliminate preventable blindness caused by AMD—a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Dark adaptation functional testing technology from MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix also provides each customer with in-practice training and treatment best practices to support the implementation and optimization of dark adaptation testing. Visit www.maculogix.com for additional information.

    Media Contact:

    Amy Hellem

    amyhellem@me.com

    (610) 304-6746

  • HARRISBURG, PENNSYLVANIA, SEPTEMBER 28, 2020–MacuLogix, Inc., a company that equips eye care professionals with the instrument, tools and education needed to effectively diagnose and manage patients with age-related macular degeneration (AMD), announces the recent publication of “Practical Opportunities in AMD Management,” the fourth in a series of annual reports aimed at reducing avoidable vision loss. Published in the September 2020 issue of Review of Optometry, this year’s report offers all the proof and tools doctors need to succeed in AMD management in an optometric setting.

    “It’s no longer only a select group of early adopters or key opinion leaders who have real world experience using dark adaptation in AMD patients and suspects,” says Gary Kirman, OD, owner of Kirman Eye in Hummelstown, PA. “I’ve been using the original AdaptDx® automated dark adaptometer since it was introduced in 2014 and now use three AdaptDx Pro™ headsets in my practice to effectively test every patient 55 years old and older examined by our three doctors. I’m excited to see this technology being adopted by more than 1,000 eye care professionals worldwide to help identify and monitor AMD at its earliest stage.”

    With the introduction of the AdaptDx Pro guided by Theia™, adoption continues to soar. This self-contained wearable headset features an on-board technician and is powered by artificial intelligence to easily fit into any practice workflow, while providing a completely reimagined user experience for the technician and the patient. The AdaptDx Pro creates a comfortable, personal dark room so patients can take the test anywhere in the office, in any light. Additionally, the medical grade hardware withstands all necessary disinfection, and the hygienic barrier that makes contact with the patient’s face is designed for single use, offering a greater level of patient confidence in this new era of point-of-care testing.

    “Practical Opportunities in AMD Management” outlines years of research to illustrate why dark adaptation is a must-have medical device in optometric practice. Additionally, the report highlights the real-world accounts of seven diverse optometrists who successfully implemented either the AdaptDx or the AdaptDx Pro in their own practices. Specifically, “Practical Opportunities in AMD Management” features papers by:

    • Steven Ferrucci, OD, FAAO
    • Jeffry Gerson, OD, FAAO
    • Paul Karpecki, OD, FAAO
    • Claudio Lagunas, OD
    • Pamela A. Lowe, OD, FAAO, Dipl. ABO
    • Julie Rodman, OD, MSc, FAAO

    “Definitively diagnosing AMD at the earliest possible stage by identifying impaired dark adaptation with the AdaptDx Pro gives patients greater agency to make good choices. This also alerts doctors to the essential need for ongoing structural and functional testing at more regular intervals than would have been determined utilizing the information from a clinical retinal evaluation alone,” says Pamela A. Lowe, OD, FAAO, Dipl. ABO, owner of Professional Eye Care Center in Niles, IL. “Make no mistake, knowing for sure that a patient has AMD makes a big difference and changes how optometry manages this vision threating disease.”

    Download “Practical Opportunities in AMD Management” here.

    About MacuLogix®

    MacuLogix, Incis revolutionizing primary eye care with elegantly simple and scientifically valid solutions. By leveraging the science of dark adaptation through its AdaptDx® and AdaptDx Pro™ guided by Theia™, MacuLogix is working to eliminate preventable blindness caused by AMD—a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Dark adaptation functional testing technology from MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be identified clinically. MacuLogix also provides each customer with personalized training and treatment best practices to support the implementation and optimization of dark adaptation testing. Visit www.maculogix.com for additional information.

    Media Contact

    Amy Hellem

    amyhellem@me.com

    (610) 304-6746


 Products

  • AdaptDx Pro™ guided by Theia™
    Our AdaptDx Pro combines the game-changing science of dark adaptation testing with patient comfort and convenience....

  • CHANGE THE FUTURE

    FOR YOUR PATIENTS AND YOUR PRACTICE

    Experience Breakthrough Technology

    Backed by 20 years of proven clinical research, the AdaptDx Pro™ is a revolutionary new way to test patients. Advanced, precision eye tracking technology automatically aligns with the eye to capture an accurate measurement of dark adaptation function.

    Meet Theia

    Our friendly on-board technician, Theia™, guides patients through the test. Powered by artificial intelligence, she delivers a uniform experience, every time. Her personalized coaching and adaptive feedback helps keep patients focused throughout the test.

    Step into the Light

    The AdaptDx Pro conforms easily to your space and workflow by eliminating the need for a darkroom. Its custom eyecups form a light-proof seal, creating a personal darkroom. You can even run multiple tests at the same time with multiple devices.

    Read Results with Ease

    An interactive LCD screen displays simple and clear instructions for the technician, making it easy to start and monitor progress. The intuitive user interface makes adoption quick and easy.

For technical assistance with this webpage please click here.